teaser
NicOx S.A. will release its 2010 half year financial results on July 30 before the opening of the market trading in France. Michele Garufi, Chairman and CEO, Eric Castaldi, Chief Financial Officer Gavin Spencer, VP Business Development will host a conference call at 3:00 pm CET.
The Company notably draws the investors’ attention to the following risk factors:
- Risques liés à la dépendance de la Société à légard du naproxcinod (Risks related to the Company’s dependence on the success of its lead product naproxcinod)
- Risques commerciaux et développements cliniques (Clinical developments and commercial risk)
- Risques liés aux contraintes réglementaires et à la lenteur des procédures d’approbation (Risks linked to regulatory constraints and slow approval procedures)
- Manque de capacités dans les domaines de la vente et du marketing (Lack of sales and marketing capabilities)
- Incertitude relative aux prix des médicaments et aux régimes de remboursement, ainsi qu’en matière de réforme des régimes d’assurance maladie (Uncertainty on drug pricing and reimbursement policies and on the reforms of the health insurance systems)
To confirm your participation please contact Irène Lalande, Investor and Media Relations Coordinator (Tel: +33 (0)4 97 24 53 11 / [email protected])
